Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone
Robin Arcani(Inserm), Régis Costello(Inserm), Marina Lafage(Aix-Marseille Université), Raphaëlle Fanciullino(Inserm), Laure Farnault(Aix-Marseille Université), Geoffroy Venton(Inserm), Bertrand Pourroy(Assistance Publique Hôpitaux de Marseille), Julien Colle(Inserm), Vadim Ivanov(Hôpital de la Conception), Pauline Roché(Hôpital de la Conception), Cédric Mercier(Inserm), Wakil Azouza(Hôpital de la Conception), Corinne Brunet(Hôpital de la Conception), Pierre Suchon(Inserm)
Cited by 1
Related Papers
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia
|Blood|2014|327
Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines
|Journal of the American Heart Association|2020|298
Meta-analysis of 65,734 Individuals Identifies TSPAN15 and SLC44A2 as Two Susceptibility Loci for Venous Thromboembolism
|The American Journal of Human Genetics|2015|274